Brazil trial enrollment has slowed to a crawl and not a Cytodyn focus…it will be a few months for the Southern Hemisphere to wake up the covid19 numbers…maybe the trial idles along…we would not need large numbers for the critical covid19 study. Maybe it comes out of left field…maybe Leronlimab is vindicated in the end. We are still losing hundreds of people a day to covid19 in the US and a half million people are out of the workforce from longhaulers, far from zero and a tragedy to be throwing the likes of Remdesivir at it when another drug can make a palpable difference. I agree with the company that focus state-side needs to be elsewhere and likely any near term catalyst will be on other therapeutic targets.

Still, if the drug has been shipped to support the trial(s) in Brazil, and Einstein is still enrolling even at a snails pace I would not be surprised at some point to see our horse Leronlimab coming around the back-stretch with no jockey and taking the lead. No one will be expecting it…think Spring and don’t count on it but don’t be surprised if it happens.